Yujin Biological

Yujin Biological is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the development of innovative small molecule drugs. The company utilizes its proprietary targeted protein degradation (TPD) platform to create therapies for oncology and autoimmune disorders, specifically targeting proteins that are difficult to inhibit with traditional small molecules. Its lead candidate, YJ-001, is a highly selective Bruton tyrosine kinase (BTK) degrader currently in Phase 1 clinical trials for the treatment of B-cell malignancies. By addressing drug resistance and improving efficacy, Yujin Biological seeks to transform the treatment landscape for patients with complex diseases. The company's pipeline includes several other protein degraders and small molecule inhibitors in various stages of pre-clinical development.